ClinicalTrials.gg
CompletedNCT01630889Updated Oct 1, 2021Results posted

Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease

A Phase 2 interventional study of Roxadustat in Chronic Kidney Disease, End Stage Renal Disease and Anemia, sponsored by FibroGen. Completed at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-01.

Primary conditionKidney Failure, ChronicRegistry: Renal Insufficiency, ChronicReclassifiedWhy we changed it
Registry
Renal Insufficiency, Chronic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Kidney Failure, Chronic
Why
  1. The study's listed conditions name Kidney Failure, Chronic, a narrower term within Renal Insufficiency, Chronic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by FibroGen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing roxadustat in Kidney Failure, Chronic — 2 open to participants now, 3 under way, 1 of them phase 3. roxadustat · Kidney Failure, Chronic.

Enrollment
15th of 15
15 · median 161
Started
2012
with 1 other
Phase 2
5 of 15
none open now
Registered
3rd of 15
by date
Lead sponsor
9 of 15
FibroGen

Among the 15 studies testing roxadustat in Kidney Failure, Chronic, this one is the 15th largest by enrollment, is one of 2 that started in 2012, is one of 5 in phase 2, and was the 3rd registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

2 of the 15 studies testing roxadustat in Kidney Failure, Chronic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About roxadustat

roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing roxadustat in Kidney Failure, Chronic, or all of them as a file.
02

Study summary

The purpose of this open-label extension study is to evaluate long-term efficacy and safety of roxadustat in maintaining hemoglobin (Hb) in participants with dialysis and non-dialysis chronic kidney disease (CKD) who have completed the Treatment Period of a roxadustat FibroGen-sponsored anemia study.

Read the detailed description

This is an open-label, long-term maintenance study of roxadustat anemia therapy in participants with dialysis and non-dialysis CKD who have completed the Treatment Period of a roxadustat FibroGen-sponsored anemia study. Participants assigned to roxadustat in the previous study will continue to receive the same roxadustat dose and dosing frequency, unless a dose adjustment is required.

03

Conditions studied

  • Chronic Kidney Disease
  • End Stage Renal Disease
  • Anemia

Browse trials for

Keywords

  • Kidney
  • ESRD
  • End Stage Renal Disease
  • Anemia
  • Oral anemia treatment
  • Hemoglobin levels
  • Hemodialysis
  • CKD
  • Chronic Kidney Disease
  • Peritoneal
  • HD
  • PD
  • Hb
  • Erythropoietin
  • Blood count
04

In context

Kidney Failure, Chronic Reclassified

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

This study's enrollment of 15 is below the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.

Browse Kidney Failure, Chronic studies →

Lead sponsor

FibroGen is the lead sponsor of 39 studies on the registry; none are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 14 (100%) have results posted.

Compared within Kidney Failure, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Renal Insufficiency, Chronic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Minimum age 18 years
  2. Completed the Treatment Period of an ongoing roxadustat FibroGen-sponsored anemia study in the United States.

Exclusion criteria

Exclusion Criteria

  1. Participants assigned to epoetin alfa in a previous ongoing roxadustat anemia study
  2. Pregnant or breastfeeding females
  3. Females of , unless using adequate ; male participants with sexual partners of childbearing potential who are not on birth control unless the male participant agrees to use adequate contraception
  4. Participants who received roxadustat in a previous study that did not demonstrate adequate response per the investigator's clinical judgment
  5. Any medical condition that in the opinion of the investigator may pose a safety risk to a participant in this study or which may interfere with study participation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Roxadustat

    Participants previously randomized to roxadustat will receive roxadustat at the same dose and frequency assigned at the last dose in the previous FibroGen study. Dose adjustments will be implemented (up to a maximum roxadustat dose of 3.0 mg/kg or 400 mg, whichever is lower) every 4 weeks to maintain Hb levels at 10.0-12 grams (g)/deciliter (dL). However, if a participant, at any dose, experiences an event of excessive hematopoiesis then the participant's dose will be immediately reduced, or an event of rapidly declining Hb then the participant's dose will be immediately increased. Participants will be permitted to receive roxadustat for up to 8 years.

    Drug: Roxadustat

Interventions

07

What researchers measure

Primary outcomes

  1. Change From Baseline in Hb Over Time

    Hb baseline was defined as the mean of the central laboratory Hb value from the baseline visit at Day 1 (prior to receiving the first dose of study drug in this study), plus any other central lab Hb values within 15 days prior to Day 1 regardless of fasting. The specific duration over which the participants were assessed was identified as "over time" for the endpoint in the study protocol. Therefore, to be consistent with the endpoint in the study protocol, an individual timepoint was not identified for this primary outcome measure.

    Time frame: Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 252, 264, 288, 312, 336, 360, and 384

Secondary outcomes

  1. Number of Participants With Hb ≥10 g/dL

    Hb baseline was defined as the mean of the central laboratory Hb value from the baseline visit at Day 1 (prior to receiving the first dose of study drug in this study), plus any other central lab Hb values within 15 days prior to Day 1 regardless of fasting.

    Time frame: Baseline up to Week 384

  2. Number of Participants Receiving Rescue Therapy (Composite of Blood Transfusions, Intravenous [IV] Iron, Erythropoiesis-Stimulating Agent [ESA])

    Time frame: Baseline up to Week 385

  3. Mean Weekly Dose of Study Drug Over Time

    Weekly dose amount was the actual total dose amounts within a week, windowed by 7-day period from Day 1. The mean weekly dose is presented for selected time periods based on timepoints reported in Outcome Measures 1 and 2.

    Time frame: Baseline up to Week 384

  4. Number of Participants With Dose Adjustments up to Week 52

    Dose adjustments include dose increases, dose interruptions, and dose reductions.

    Time frame: Baseline up to Week 52

  5. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

    An adverse event (AE) was any untoward medical event in a participant who received study drug whether or not the event is considered drug related. TEAEs were defined as any event that either began or worsened after the first administration of study drug and within 28 days of the last dose. Serious AE criteria included death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed here. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Baseline up to Week 385

08

Results

Posted Oct 1, 2021

Participant flow

Participant flow — Overall Study
MilestoneRoxadustat
Started15
Received at least 1 dose of study drug15
Completed5
Not completed10
Withdrew: Death2
Withdrew: Withdrawal by subject1
Withdrew: Other than specified2
Withdrew: Lost to follow-up4
Withdrew: Other1

Outcome measures

PrimaryChange From Baseline in Hb Over Time

Hb baseline was defined as the mean of the central laboratory Hb value from the baseline visit at Day 1 (prior to receiving the first dose of study drug in this study), plus any other central lab Hb values within 15 days prior to Day 1 regardless of fasting. The specific duration over which the participants were assessed was identified as "over time" for the endpoint in the study protocol. Therefore, to be consistent with the endpoint in the study protocol, an individual timepoint was not identified for this primary outcome measure.

Time frame:
Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 252, 264, 288, 312, 336, 360, and 384
Reported as:
Mean · g/dL
Change From Baseline in Hb Over Time
g/dLRoxadustat
Baseline10.05 ± 0.931
Change at Week 81.26 ± 0.633
Change at Week 241.58 ± 0.959
Change at Week 481.94 ± 1.324
Change at Week 722.54 ± 1.234
Change at Week 961.18 ± 1.141
Change at Week 1201.61 ± 0.815
Change at Week 1441.96 ± 0.804
Change at Week 1681.40 ± 1.441
Change at Week 1921.02 ± 1.063
Change at Week 2161.34 ± 1.062
Change at Week 2401.02 ± 0.779
Change at Week 2641.63 ± 1.640
Change at Week 2880.00 ± 1.647
Change at Week 3120.23 ± 0.416
Change at Week 3360.70 ± 0.000
Change at Week 360-1.20 ± NA
Change at Week 384-0.40 ± NA
SecondaryNumber of Participants With Hb ≥10 g/dL

Hb baseline was defined as the mean of the central laboratory Hb value from the baseline visit at Day 1 (prior to receiving the first dose of study drug in this study), plus any other central lab Hb values within 15 days prior to Day 1 regardless of fasting.

Time frame:
Baseline up to Week 384
Reported as:
Count of participants · Participants
Number of Participants With Hb ≥10 g/dL
ParticipantsRoxadustat
Baseline9
Week 813
Week 2413
Week 4813
Week 7211
Week 967
Week 1208
Week 1447
Week 1685
Week 1925
Week 2165
Week 2405
Week 2644
Week 2883
Week 3123
Week 3362
Week 3601
Week 3841
SecondaryNumber of Participants Receiving Rescue Therapy (Composite of Blood Transfusions, Intravenous [IV] Iron, Erythropoiesis-Stimulating Agent [ESA])
Time frame:
Baseline up to Week 385
Reported as:
Count of participants · Participants
Number of Participants Receiving Rescue Therapy (Composite of Blood Transfusions, Intravenous [IV] Iron, Erythropoiesis-Stimulating Agent [ESA])
ParticipantsRoxadustat
Blood Transfusion1
IV Iron5
ESA1
No Rescue Therapy8
SecondaryMean Weekly Dose of Study Drug Over Time

Weekly dose amount was the actual total dose amounts within a week, windowed by 7-day period from Day 1. The mean weekly dose is presented for selected time periods based on timepoints reported in Outcome Measures 1 and 2.

Time frame:
Baseline up to Week 384
Reported as:
Mean · mg
Mean Weekly Dose of Study Drug Over Time
mgRoxadustat
Week 1-4257.0 ± 140.33
Week 5 - 8252.4 ± 115.26
Week 21 - 24282.3 ± 218.07
Week 41 - 48318.4 ± 216.90
Week 61 - 72236.7 ± 108.57
Week 85 - 96155.9 ± 114.27
Week 109 - 120142.8 ± 105.10
Week 133 - 144140.3 ± 101.03
Week 157 - 168152.2 ± 111.19
Week 181 - 192195.6 ± 184.77
Week 205 - 216209.4 ± 156.13
Week 229 - 240225.7 ± 164.58
Week 253 - 264327.9 ± 169.82
Week 277 - 288324.0 ± 190.75
Week 301 - 312319.2 ± 196.98
Week 325 - 336413.3 ± 180.37
Week 349 - 360389.6 ± 156.15
Week 373 - 384250.0 ± NA
SecondaryNumber of Participants With Dose Adjustments up to Week 52

Dose adjustments include dose increases, dose interruptions, and dose reductions.

Time frame:
Baseline up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Dose Adjustments up to Week 52
ParticipantsRoxadustat
Participants without Change1
Participants with 1 Dose Increase5
Participants with 2 Dose Increases1
Participants with >2 Dose Increases6
Participants with 1 Dose Interruption1
Participants with 2 Dose Interruptions1
Participants with >2 Dose Interruptions0
Participants with 1 Dose Reduction2
Participants with 2 Dose Reductions8
Participants with >2 Dose Reductions2
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

An adverse event (AE) was any untoward medical event in a participant who received study drug whether or not the event is considered drug related. TEAEs were defined as any event that either began or worsened after the first administration of study drug and within 28 days of the last dose. Serious AE criteria included death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed here. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Baseline up to Week 385
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsRoxadustat
Any TEAEs14
Serious TEAEs9

Adverse events

Collected over Baseline up to Week 385. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roxadustat2/15 (13.3%)9/15 (60%)14/15 (93.3%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventRoxadustat
Acute myocardial infarctionCardiac disorders2/15
Angina pectorisCardiac disorders2/15
Atrial fibrillationCardiac disorders2/15
Cardiac failure congestiveCardiac disorders2/15
PneumoniaInfections and infestations2/15
Urinary tract infectionInfections and infestations2/15
Chronic kidney diseaseRenal and urinary disorders2/15
Hemorrhagic anaemiaBlood and lymphatic system disorders1/15
Acute coronary syndromeCardiac disorders1/15
Angina unstableCardiac disorders1/15
Most frequent other events
Showing 10 of 110
Most frequent other events
EventRoxadustat
Upper respiratory tract infectionInfections and infestations6/15
CoughRespiratory, thoracic and mediastinal disorders5/15
Abdominal painGastrointestinal disorders3/15
BronchitisInfections and infestations3/15
Urinary tract infectionInfections and infestations3/15
Viral upper respiratory tract infectionInfections and infestations3/15
GoutMetabolism and nutrition disorders3/15
HypoglycaemiaMetabolism and nutrition disorders3/15
Muscle spasmsMusculoskeletal and connective tissue disorders3/15
Vaginal haemorrhageReproductive system and breast disorders2/10

Baseline characteristics

Participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Roxadustat
Mean64.6 ± 12.02
Sex: Female, Male
Sex: Female, Male(Participants)Roxadustat
Female10
Male5
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Roxadustat
Hispanic or Latino6
Not Hispanic or Latino9
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Roxadustat
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White13
More than one race1
Unknown or Not Reported0
09

Study locations

7 sites
  • APEX Research
    Riverside, California 92505, United States
  • Greenbelt, Maryland 20770, United States
  • Mountain Kidney & HTN Associates, PA
    Asheville, North Carolina 28801, United States
  • Arlington Nephrology
    Arlington, Texas 76015, United States
  • Consolidated Medical Plaza
    Caguas, 00725, Puerto Rico
  • CAIMED School of Medicine
    Ponce, 00716, Puerto Rico
  • San Juan, 00918, Puerto Rico
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2012 to primary completion in Dec 2019, 90 months.

Results were first posted in Oct 2021, 1 year 9 months after primary completion. A results delay was requested in Jun 2020.

Of 26 industry-sponsored phase 2 interventional studies under Kidney Failure, Chronic, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's 90 months is above that.

Counting every sponsor, half of 67 studies reached it within 32 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2012
First posted
Jun 28, 2012
StartActual
May 18, 2012
Primary completionActual
Dec 12, 2019
CompletionActual
Dec 12, 2019
Results delay requested
Jun 25, 2020
Results first posted
Oct 1, 2021
Last update
Oct 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01630889
Lead sponsor
FibroGen
Responsible party
Sponsor
First posted
Jun 28, 2012
Start date
May 18, 2012
Primary completion
Dec 12, 2019
Completion
Dec 12, 2019
Results posted
Oct 1, 2021
Last update
Oct 1, 2021

Study contacts

Peony Yu
study director · FibroGen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roxadustat

Start the discussion